Targeting synovial neoangiogenesis in rheumatoid arthritis

Autoimmun Rev. 2017 Jun;16(6):594-601. doi: 10.1016/j.autrev.2017.04.005. Epub 2017 Apr 14.

Abstract

In Rheumatoid arthritis (RA), neoangiogenesis is an early and crucial event to promote the development of the hyperplasic proliferative pathologic synovium. Endothelial cells are critical for the formation of new blood vessels since they highly contribute to angiogenesis and vasculogenesis. Current therapies in RA target the inflammatory consequences of autoimmune activation and despite major improvements these last years still refractory patients or incomplete responders may be seen raising the point of the need to identify complementary additive and innovative therapies. This review resumes the mechanisms of synovial neoangiogenesis in RA, including recent insights on the implication of vasculogenesis, and the regulation of synovial neoangiogenesis by angiogenic and inflammatory mediators. In line with the recent development of vascular-targeted therapies used in cancer and beyond, we also discuss possible therapeutic implications in RA, in particular the combination of targeted immunotherapies with anti-angiogenic molecules.

Keywords: Endothelial cells; Rheumatoid arthritis; Synovial angiogenesis; Vasculogenesis.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / pathology
  • Blood Vessels / pathology
  • Humans
  • Hypoxia / pathology
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology
  • Synovial Membrane / blood supply*
  • Synovial Membrane / pathology